Role of Medical Therapy for Nonvariceal Upper Gastrointestinal Bleeding

Gastrointestinal Endoscopy Clinics of North America

Volumn 25, Issue 3, 2015, Pages 463-478

  Fortinsky, Kyle J ^a   Bardou, Marc ^b   Barkun, Alan N ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Erythromycin; Iron replacement therapy; Nasogastric lavage; Nonvariceal upper gastrointestinal bleeding; Proton pump inhibitors; Red blood cell transfusions; Tranexamic acid

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; ERYTHROMYCIN; ESOMEPRAZOLE; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; FRESH FROZEN PLASMA; HEMOGLOBIN; HETASTARCH; HISTAMINE H2 RECEPTOR ANTAGONIST; IRON; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PANTOPRAZOLE; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; SOMATOSTATIN; TRANEXAMIC ACID; GASTROINTESTINAL AGENT;

ANEMIA; BACTERIUM DETECTION; BLEEDING; BONE METABOLISM; CLOSTRIDIUM DIFFICILE INFECTION; CONTINUOUS INFUSION; CRYSTALLOID; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; DUODENUM ULCER; ERYTHROCYTE TRANSFUSION; FLUID RESUSCITATION; FRACTURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOSPITAL ADMISSION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOVOLEMIC SHOCK; INCIDENCE; INTENSIVE CARE UNIT; INTERSTITIAL NEPHRITIS; IRON THERAPY; LOW DRUG DOSE; MALABSORPTION; MORTALITY; NASOGASTRIC TUBE; NONVARICEAL UPPER GASTROINTESTINAL BLEEDING; PEPTIC ULCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT INTERVAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; REFLUX ESOPHAGITIS; REVIEW; SEROLOGY; SINGLE DRUG DOSE; STOMACH PH; STRESS ULCER; SUPPLEMENTATION; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; ULCER; UPPER GASTROINTESTINAL BLEEDING; UREA BREATH TEST; DISEASE MANAGEMENT; GASTROINTESTINAL HEMORRHAGE;

DISEASE MANAGEMENT; GASTROINTESTINAL AGENTS; GASTROINTESTINAL HEMORRHAGE; HUMANS;

EID: 84937636766     PISSN: 10525157     EISSN: 15581950     Source Type: Journal    
DOI: 10.1016/j.giec.2015.02.003     Document Type: Review

References (102)

1. Button L.A., Roberts S.E., Evans P.A., et al. Hospitalized incidence and case fatality for upper gastrointestinal bleeding from 1999 to 2007: a record linkage study. Aliment Pharmacol Ther 2011, 33:64-76.
2. Barkun A.N., Bardou M., Kuipers E.J., et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010, 152:101-113.
3. Lau J.Y., Sung J., Hill C., et al. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion 2011, 84:102-113.
4. Bardhan K.D., Williamson M., Royston C., et al. Admission rates for peptic ulcer in the Trent region, UK, 1972-2000. Changing pattern, a changing disease?. Dig Liver Dis 2004, 36:577-588.
5. Soplepmann J., Peetsalu A., Peetsalu M., et al. Peptic ulcer haemorrhage in Tartu County, Estonia: epidemiology and mortality risk factors. Scand J Gastroenterol 1997, 32:1195-1200.
6. Barkun A., Sabbah S., Enns R., et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004, 99:1238-1246.
7. Hearnshaw S.A., Logan R.F., Lowe D., et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011, 60:1327-1335.
8. Liu N.J., Lee C.S., Tang J.H., et al. Outcomes of bleeding peptic ulcers: a prospective study. J Gastroenterol Hepatol 2007, 23(8 Pt 2):e340-e347.
9. Crooks C., Card T., West J. Reductions in 28-day mortality following hospital admission for upper gastrointestinal hemorrhage. Gastroenterology 2011, 141:62-70.
10. Lanas A., Carrera-Lasfuentes P., Garcia-Rodriguez L.A., et al. Outcomes of peptic ulcer bleeding following treatment with proton pump inhibitors in routine clinical practice: 935 patients with high- or low-risk stigmata. Scand J Gastroenterol 2014, 49:1181-1190.
11. Laine L., Jensen D.M. Management of patients with ulcer bleeding. Am J Gastroenterol 2012, 107:345-360. [quiz: 61].
12. Greenspoon J., Barkun A. A summary of recent recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Pol Arch Med Wewn 2010, 120:341-346.
13. Wee E. Management of nonvariceal upper gastrointestinal bleeding. J Postgrad Med 2011, 57:161-167.
14. Myburgh J.A., Finfer S., Bellomo R., et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012, 367:1901-1911.
15. Bunn F., Trivedi D., Ashraf S. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev 2011, (3). CD001319.
16. Jairath V., Hearnshaw S., Brunskill S.J., et al. Red cell transfusion for the management of upper gastrointestinal haemorrhage. Cochrane Database Syst Rev 2010, (9). CD006613.
17. Villanueva C., Colomo A., Bosch A. Transfusion for acute upper gastrointestinal bleeding. N Engl J Med 2013, 368:1362-1363.
18. Shalev A., Zahger D., Novack V., et al. Incidence, predictors and outcome of upper gastrointestinal bleeding in patients with acute coronary syndromes. Int J Cardiol 2012, 157:386-390.
19. Jairath V., Kahan B.C., Logan R.F., et al. Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians. Transfusion 2011, 51:1940-1948.
20. Rohde J.M., Dimcheff D.E., Blumberg N., et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA 2014, 311:1317-1326.
21. Kahan B.C., Jairath V., Murphy M.F., et al. Update on the transfusion in gastrointestinal bleeding (TRIGGER) trial: statistical analysis plan for a cluster-randomised feasibility trial. Trials 2013, 14:206.
22. Razzaghi A., Barkun A.N. Platelet transfusion threshold in patients with upper gastrointestinal bleeding: a systematic review. J Clin Gastroenterol 2012, 46:482-486.
23. Pallin D.J., Saltzman J.R. Is nasogastric tube lavage in patients with acute upper GI bleeding indicated or antiquated?. Gastrointest Endosc 2011, 74:981-984.
24. Witting M.D. You wanna do what?! Modern indications for nasogastric intubation. J Emerg Med 2007, 33:61-64.
25. Palamidessi N., Sinert R., Falzon L., et al. Nasogastric aspiration and lavage in emergency department patients with hematochezia or melena without hematemesis. Acad Emerg Med 2010, 17:126-132.
26. Pateron D., Vicaut E., Debuc E., et al. Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial. Ann Emerg Med 2011, 57:582-589.
27. Barkun A., Bardou M., Marshall J.K. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003, 139:843-857.
28. Colak S., Erdogan M.O., Sekban H., et al. Emergency diagnosis of upper gastrointestinal bleeding by detection of haemoglobin in nasogastric aspirate. J Int Med Res 2013, 41:1825-1829.
29. Iwasaki H., Shimura T., Yamada T., et al. Novel nasogastric tube-related criteria for urgent endoscopy in nonvariceal upper gastrointestinal bleeding. Dig Dis Sci 2013, 58(9):2564-2571.
30. Aljebreen A.M., Fallone C.A., Barkun A.N. Nasogastric aspirate predicts high-risk endoscopic lesions in patients with acute upper-GI bleeding. Gastrointest Endosc 2004, 59:172-178.
31. Gralnek I.M., Barkun A.N., Bardou M. Management of acute bleeding from a peptic ulcer. N Engl J Med 2008, 359:928-937.
32. Pitera A., Sarko J. Just say no: gastric aspiration and lavage rarely provide benefit. Ann Emerg Med 2010, 55:365-366.
33. Anderson R.S., Witting M.D. Nasogastric aspiration: a useful tool in some patients with gastrointestinal bleeding. Ann Emerg Med 2010, 55:364-365.
34. Javad Ehsani Ardakani M., Zare E., Basiri M., et al. Erythromycin decreases the time and improves the quality of EGD in patients with acute upper GI bleeding. Gastroenterol Hepatol Bed Bench 2013, 6:195-201.
35. Frossard J.L., Spahr L., Queneau P.E., et al. Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Gastroenterology 2002, 123:17-23.
36. Barkun A.N., Bardou M., Martel M., et al. Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc 2010, 72:1138-1145.
37. Bai Y., Guo J.F., Li Z.S. Meta-analysis: erythromycin before endoscopy for acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 2011, 34:166-171.
38. Szary N.M., Gupta R., Choudhary A., et al. Erythromycin prior to endoscopy in acute upper gastrointestinal bleeding: a meta-analysis. Scand J Gastroenterol 2011, 46:920-924.
39. Altraif I., Handoo F.A., Aljumah A., et al. Effect of erythromycin before endoscopy in patients presenting with variceal bleeding: a prospective, randomized, double-blind, placebo-controlled trial. Gastrointest Endosc 2011, 73:245-250.
40. Coffin B., Pocard M., Panis Y., et al. Erythromycin improves the quality of EGD in patients with acute upper GI bleeding: a randomized controlled study. Gastrointest Endosc 2002, 56:174-179.
41. Sreedharan A., Martin J., Leontiadis G.I., et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010, (7). CD005415.
42. Lau J.Y., Leung W.K., Wu J.C., et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007, 356:1631-1640.
43. Laine L., Shah A., Bemanian S. Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers. Gastroenterology 2008, 134:1836-1841.
44. Lin H.J., Lo W.C., Cheng Y.C., et al. Role of intravenous omeprazole in patients with high-risk peptic ulcer bleeding after successful endoscopic epinephrine injection: a prospective randomized comparative trial. Am J Gastroenterol 2006, 101:500-505.
45. Leontiadis G.I., Sharma V.K., Howden C.W. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc 2007, 82:286-296.
46. Al-Sabah S., Barkun A.N., Herba K., et al. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2008, 6:418-425.
47. Barkun A.N., Bardou M., Kuipers E.J., et al. How early should endoscopy be performed in suspected upper gastrointestinal bleeding?. Am J Gastroenterol 2012, 107:328-329.
48. Imperiale T.F., Birgisson S. Somatostatin or octreotide compared with H2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Ann Intern Med 1997, 127:1062-1071.
49. Arabi Y., Al Knawy B., Barkun A.N., et al. Pro/con debate: octreotide has an important role in the treatment of gastrointestinal bleeding of unknown origin?. Crit Care 2006, 10:218.
50. Bennett C., Klingenberg S.L., Langholz E., et al. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2014, (11). CD006640.
51. Manno D., Ker K., Roberts I. How effective is tranexamic acid for acute gastrointestinal bleeding?. BMJ 2014, 348:g1421.
52. Bardou M., Martin J., Barkun A. Intravenous proton pump inhibitors: an evidence-based review of their use in gastrointestinal disorders. Drugs 2009, 69:435-448.
53. Ghassemi K.A., Kovacs T.O., Jensen D.M. Gastric acid inhibition in the treatment of peptic ulcer hemorrhage. Curr Gastroenterol Rep 2009, 11:462-469.
54. Vorder Bruegge W.F., Peura D.A. Stress-related mucosal damage: review of drug therapy. J Clin Gastroenterol 1990, 12(Suppl 2):S35-S40.
55. Laine L., McQuaid K.R. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol 2009, 7:33-47. [quiz: 1-2].
56. Forrest J.A., Finlayson N.D., Shearman D.J. Endoscopy in gastrointestinal bleeding. Lancet 1974, 2:394-397.
57. Sung J.J., Barkun A., Kuipers E.J., et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med 2009, 150:455-464.
58. Barkun A.N., Adam V., Sun-g J.J., et al. Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding. Pharmacoeconomics 2010, 28:217-230.
59. Sachar H., Vaidya K., Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med 2014, 174:1755-1762.
60. Leontiadis G.I., Sharma V.K., Howden C.W. Systematic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia-a post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther 2005, 21:1055-1061.
61. Hoie O., Stallemo A., Matre J., et al. Effect of oral lansoprazole on intragastric pH after endoscopic treatment for bleeding peptic ulcer. Scand J Gastroenterol 2009, 44:284-288.
62. Laine L., Peterson W.L. Bleeding peptic ulcer. N Engl J Med 1994, 331:717-727.
63. Cheng H.C., Wu C.T., Chang W.L., et al. Double oral esomeprazole after a 3-day intravenous esomeprazole infusion reduces recurrent peptic ulcer bleeding in high-risk patients: a randomised controlled study. Gut 2014, 63:1864-1872.
64. Yang Y.X., Metz D.C. Safety of proton pump inhibitor exposure. Gastroenterology 2010, 139:1115-1127.
65. Dial S., Delaney J.A., Barkun A.N., et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989-2995.
66. Tleyjeh I.M., Bin Abdulhak A.A., Riaz M., et al. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One 2012, 7:e50836.
67. Eom C.S., Jeon C.Y., Lim J.W., et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011, 183:310-319.
68. Filion K.B., Chateau D., Targownik L.E., et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014, 63:552-558.
69. Barkun A.N., Bardou M., Pham C.Q., et al. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol 2012, 107:507-520. [quiz: 21].
70. Khalili H., Huang E.S., Jacobson B.C., et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012, 344:e372.
71. Yu E.W., Bauer S.R., Bain P.A., et al. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011, 124:519-526.
72. Jo Y., Park E., Ahn S.B., et al. A proton pump inhibitor's effect on bone metabolism mediated by osteoclast action in old age: a prospective randomized study. Gut Liver 2014, [Epub ahead of print].
73. Moayyedi P., Yuan Y., Leontiadis G., et al. Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update. Can J Gastroenterol 2013, 27:593-595.
74. Leontiadis G.I., Moayyedi P. Proton pump inhibitors and risk of bone fractures. Curr Treat Options Gastroenterol 2014, 12:414-423.
75. Hess M.W., Hoenderop J.G., Bindels R.J., et al. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012, 36:405-413.
76. Lam J.R., Schneider J.L., Zhao W., et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 2013, 310:2435-2442.
77. Muriithi A.K., Leung N., Valeri A.M., et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis 2014, 64:558-566.
78. Ghebremariam Y.T., LePendu P., Lee J.C., et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 2013, 128:845-853.
79. Lima J.P., Brophy J.M. The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Med 2010, 8:81.
80. Schneider-Lindner V., Filion K.B., Brophy J.M. Adverse outcomes associated with use of proton pump inhibitors and clopidogrel. JAMA 2009, 302:29-30. [author reply: 1].
81. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002, 346:2033-2038.
82. Sung J.J., Lau J.Y., Ching J.Y., et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010, 152:1-9.
83. Lai K.C., Chu K.M., Hui W.M., et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006, 4:860-865.
84. Chan F.K., Ching J.Y., Hung L.C., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005, 352:238-244.
85. Wong G.L., Wong V.W., Chan Y., et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 2009, 137:525-531.
86. Talley N.J., Li Z. Helicobacter pylori: testing and treatment. Expert Rev Gastroenterol Hepatol 2007, 1:71-79.
87. Sfarti C., Stanciu C., Cojocariu C., et al. 13C-urea breath test for the diagnosis of Helicobacter pylori infection in bleeding duodenal ulcer. Rev Med Chir Soc Med Nat Iasi 2009, 113:704-709.
88. Sanchez-Delgado J., Gene E., Suarez D., et al. Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. Am J Gastroenterol 2011, 106:398-405.
89. Gisbert J.P., Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol 2006, 101:848-863.
90. Stenstrom B., Mendis A., Marshall B. Helicobacter pylori-the latest in diagnosis and treatment. Aust Fam Physician 2008, 37:608-612.
91. Ramirez-Lazaro M.J., Lario S., Casalots A., et al. Real-time PCR improves Helicobacter pylori detection in patients with peptic ulcer bleeding. PLoS One 2011, 6:e20009.
92. Fock K.M. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther 2014, 40:250-260.
93. Plummer M., Franceschi S., Vignat J., et al. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 2015, 136:487-490.
94. Verdon F., Burnand B., Stubi C.L., et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ 2003, 326:1124.
95. Bruner A.B., Joffe A., Duggan A.K., et al. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet 1996, 348:992-996.
96. Bager P., Dahlerup J.F. Lack of follow-up of anaemia after discharge from an upper gastrointestinal bleeding centre. Dan Med J 2013, 60:A4583.
97. Rockall T.A., Logan R.F., Devlin H.B., et al. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996, 38:316-321.
98. Bager P., Dahlerup J.F. Randomised clinical trial: oral vs. intravenous iron after upper gastrointestinal haemorrhage-a placebo-controlled study. Aliment Pharmacol Ther 2014, 39:176-187.
99. Bayraktar U.D., Bayraktar S. Treatment of iron deficiency anemia associated with gastrointestinal tract diseases. World J Gastroenterol 2010, 16:2720-2725.
100. Hallberg L., Ryttinger L., Solvell L. Side-effects of oral iron therapy. A double-blind study of different iron compounds in tablet form. Acta Med Scand Suppl 1966, 459:3-10.
101. Cancelo-Hidalgo M.J., Castelo-Branco C., Palacios S., et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin 2013, 29:291-303.
102. Sas G., Nemesanszky E., Brauer H., et al. On the therapeutic effects of trivalent and divalent iron in iron deficiency anaemia. Arzneimittelforschung 1984, 34:1575-1579.